Recherche
-
Validation of a Denoising Method Using Deep Learning-Based Reconstruction to Quantify Multiple Sclerosis Lesion Load on Fast FLAIR Imaging.
(American Journal of Neuroradiology. vol. 43, n° 8, pp. 1099-1106, 2022-07-28)Article de revueLibre accès -
Effect of cognitive rehabilitation on neuropsychological and semiecological testing and on daily cognitive functioning in multiple sclerosis: The REACTIV randomized controlled study
(2020-08-15)Document de travail - Pré-publicationLibre accès -
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 6, 2023-09-22)Article de revueLibre accès -
Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
(Brain Sciences. vol. 12, n° 2, pp. 183, 2022-01-29)Article de revueLibre accès -
Differential vulnerability of thalamic nuclei in multiple sclerosis
(Multiple Sclerosis Journal, 2022-08-12)Article de revueLibre accès -
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
(Neurotherapeutics. vol. 19, n° 2, pp. 476-490, 2022-03)Article de revueLibre accès -
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
(Neurology. vol. 100, n° 12, pp. e1296-e1308, 2023-03-21)Article de revueLibre accès -
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 3, 2023-02-21)Article de revueLibre accès -
MRI characteristics of MOG-Ab associated disease in adults: an update
(2021)Document de travail - Pré-publicationLibre accès -
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification among Natalizumab Users in France
(JAMA Neurology. vol. 77, n° 1, pp. 94-102, 2020-01-01)Article de revueLibre accès